Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)

Jason R. Gotlib, MDMS, Deepti Radia, MD, Daniel J. DeAngelo, MD, Prithviraj Bose, MD, Mark W Drummond, PhDMD, Elizabeth O. Hexner, MDMS, William A Robinson, MD PhD, Maureen G. Conlan, MD, Ronny G. Oren, MS, Hongliang Shi, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 351.

https://doi.org/10.1182/blood-2018-99-112017

Published: 2018

Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update

Tim H. Brümmendorf, MD, Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Carlo Gambacorti-Passerini, MD, Jeff H. Lipton, PhD, MD

Blood (2013) 122 (21): 2723.

https://doi.org/10.1182/blood.V122.21.2723.2723

Published: 2013

Journal Articles

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Jorge E. Cortes, MD, H. Jean Khoury, MD, Andreas Hochhaus, MD, Jane F Apperley, MD, Stephen G. O'Brien, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Maureen G. Conlan, MD, Hagop M. Kantarjian, MD, Tim H. Brümmendorf, MD

Blood (2013) 122 (21): 1484.

https://doi.org/10.1182/blood.V122.21.1484.1484

Published: 2013

Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Jeff H. Lipton, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD

Blood (2013) 122 (21): 4025.

https://doi.org/10.1182/blood.V122.21.4025.4025

Published: 2013

Journal Articles

A Phase I Study of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Relapsed/Refractory Acute Leukemia

Lisa M. Arfons, MD, Mark H. Kirschbaum, MD, Timothy W. Synold, PharmD, Hillard M. Lazarus, MD, Tamila L. Kindwall-Keller, DO, Mary J. Laughlin, MD, Maureen G. Conlan, MD, Joe Seroogy, Larry Doyle, Brenda W. Cooper, MD

Blood (2008) 112 (11): 4038.

https://doi.org/10.1182/blood.V112.11.4038.4038

Published: 2008

Journal Articles

Antibodies to S-303 Treated RBC Prepared with the Original Treatment Process (OSRBC) for Pathogen Inactivation Do Not React with RBC Prepared with a Modified S-303 Treatment Process (MSRBC).

Maureen G. Conlan, MD, George Garratty, PhD, FRCPath, Grace Castro, Anna Erickson, Mary Ann Schott, Pat Arndt, David Cook, PhD, Laurence Corash, MD, Adonis Stassinopoulos, PhD

Blood (2005) 106 (11): 430.

https://doi.org/10.1182/blood.V106.11.430.430

Published: 2005

Journal Articles

Transfusion of S-303 Treated RBCs To Treat Acute Anemia during or Following Cardiac Surgery: Results of a Phase III Trial.

Richard J. Benjamin, MB CHB PhD, Jeffrey McCullough, MD, Paul D. Mintz, MD, Edward L. Snyder, MD, William D. Spotnitz, MD, David Wages, MD, PhD, Lindsey Wood, PhD, Jaime Houghton, Jin-Sying Lin, PhD, Laurence Corash, MD, Maureen G. Conlan, MD

Blood (2004) 104 (11): 381.

https://doi.org/10.1182/blood.V104.11.381.381

Published: 2004

Journal Articles

Antibody Formation to S-303-Treated RBCS in the Setting of Chronic RBC Transfusion.

Maureen G. Conlan, MD, Adonis Stassinopoulos, PhD, George Garratty, PhD, David Wages, MD, PhD, Laurence Corash, MD, Lindsey Wood, PhD, Steven R. Sloan, MD, Richard J. Labotka, MD

Blood (2004) 104 (11): 382.

https://doi.org/10.1182/blood.V104.11.382.382

Published: 2004

Journal Articles

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

Blood (2004) 104 (5): 1534–1541.

https://doi.org/10.1182/blood-2003-12-4443

Published: 2004

NARROW

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

A Phase I Study of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Relapsed/Refractory Acute Leukemia

Antibodies to S-303 Treated RBC Prepared with the Original Treatment Process (OSRBC) for Pathogen Inactivation Do Not React with RBC Prepared with a Modified S-303 Treatment Process (MSRBC).

Transfusion of S-303 Treated RBCs To Treat Acute Anemia during or Following Cardiac Surgery: Results of a Phase III Trial.

Antibody Formation to S-303-Treated RBCS in the Setting of Chronic RBC Transfusion.

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only